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Abstract
Hepatic complications of allogeneic hematopoietic cell transplantation contribute substantially to the overall success of the
procedure and represent a major cause of morbidity and mortality. Early hepatic complications consist of the sinusoidal
obstruction syndrome, drug toxicities, infections, and acute graft-versus-host disease, while late hepatic complications
consist of chronic graft-versus host disease, chronic viral hepatitis, and iron overload states. Successful management of
the hepatic complications of allogeneic hematopoietic cell transplantation is dependent on several factors. These include
the recognition and elimination of any pre-transplant risk factors for these problems and the development of strategies to
evaluate and prevent them in both the early and later post-transplant periods. The aims of the present review are 1) to
identify the early and late hepatic complications of allogeneic hematopoietic cell transplantation, in the chronological order
in which they occur, 2) to characterize the diagnostic procedures used to identify them, and finally 3) to present the cur-
rent therapeutic approaches used to manage these problems. 
(Turk J Hematol 2008; 25: 111-23)
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Özet
Allojenik hematopoetik hücre naklinin (AHHN) hepatik komplikasyonlar› iﬂlemin genel baﬂar›s›nda önemli bir paya sahiptir
ve iﬂleme ba¤l› morbidite ve mortalitenin baﬂl›ca nedenlerindendir. Erken hepatik komplikasyonlar aras›nda sinüzoidal
obstrüksiyon sendromu, ilaca ba¤l› hepatik toksisite, infeksiyonlar ve akut graft vesus host hastal›¤› say›labilir. Kronik graft
vesus host hastal›¤›, kronik viral hepatit ve demir yüklenmesi geç hepatik komplikasyonlar aras›ndad›r. AHHN sonras› izle-
nen hepatik komplikasyonlar›n baﬂar›l› bir ﬂekilde müdahele edilebilmesi için çeﬂitli etmenlere ba¤l›d›r. Erken ve geç trans-
plant öncesi dönemde bu nakil öncesi risk faktörlerinin farkedilmesi ve düzeltilmesi için strateji geliﬂtirilmesi gereklidir. Bu
derlemede 1) alloHHN sonras› erken ve geç hepatik komplikasyonlar›n tan›nmas› ve kronolojik s›ralamas›n›n yap›lmas›; 
2) Kullan›lan tan›sal yöntemlerin tan›t›lmas› ve 3) Bu problemler ile baﬂetmede kullan›lan güncel tedavi yaklaﬂ›mlar›n›n
aktar›m› hedeflenmektedir. (Turk J Hematol 2008; 25: 111-23)
Anahtar kelimeler: Allojeneik hematopoietik hücre nakli, hepatik komplikasyonlar, karaci¤er, kemik ili¤i transplantasyonu
Geliﬂ tarihi: 5 Kas›m 2007 Kabul tarihi: 18 Mart 2008Introduction
Allogeneic hematopoietic cell transplantation (alloHCT) has 
become the standard treatment for various hemato/oncological 
diseases as well as certain autoimmune disorders [1]. Current 
estimates of the number of alloHCT procedures performed annually
worldwide are 12,000 to 15,000. The first year transplant-related
mortality after alloHCT averages 30% in HLA-identical sibling 
transplants [1]. 
Hepatic complications are a well-known cause of early 
post-alloHCT morbidity and mortality, occurring in 80% of cases
[2]. Infections, drug toxicity, the sinusoidal obstruction syndrome
(SOS) and acute graft-versus-host disease (aGVHD) are the
most frequent causes of liver abnormalities in the early 
post-transplant period. Chronic viral hepatitis, chronic GVHD
(cGVHD) and iron overload states are the most frequent causes
of late liver abnormalities [2-6] (Table 1). The aims of the present
review are 1) to identify the causes of early and late liver 
abnormalities of alloHCT in the order that physicians are likely to
encounter them, 2) to characterize the diagnostic procedures
used to specifically identify them, and 3) to present the current
therapeutic approaches used to manage these problems. 
A- Pre-transplant considerations
Several studies have defined the pre-transplant risk factors
that are associated with post-transplant liver-related morbidity
and mortality [2,3,6]. Some of the risk factors, such as elevated
transaminases levels, are well recognized, whereas some, such
as presence of pre-existing occult liver disease, are often 
unrecognized and remain unsettled (Table 2). 
Biochemical liver tests, including the serum aminotransferases
(alanine aminotransferase-ALT, aspartate aminotransferase-AST),
alkaline phosphatase, gamma-glutamyl transpeptidase (GGT), 
bilirubin and albumin levels, and prothrombin time assess 
hepatocellular necrosis, cholestasis, and hepatic synthetic 
capacity. These tests have limited sensitivity and specificity, do 
not all reflect liver function, and provide limited information 
regarding the presence or severity of complications of liver disease. 
A hepatitis virus serology panel consisting of an assessment
of hepatitis A (HAV), B (HBV), D (HDV) and C (HCV) virus, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human 
immunodeficiency virus (HIV) infections are routinely obtained in
the pre-transplant period on both recipient and donor. 
Abdominal sonography should be performed to identify any 
abnormality of abdominal organs. 
For the assessment of asymptomatic aminotransfe-
rases elevation: During pre-transplant evaluation, the 
establishment of asymptomatic individuals with mild-to-moderate
elevations in aminotransferase levels represents a common 
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Elevated ALT and AST levels
Evaluate viral serologies and iran
studies
Evaluate the presence of reversible causes
Observation Further evaluation for
potential liver disease (liver
biopsy and imaging studies)
Evaluate other
etiological causes
(Autoimmune Panel, Metabolic Diease)
Re-test
Confirmed the abnormal liver tests
Clinical history and physical examination
Negative
Negative
Negative
(drug, alcohol, obesity)
Positive
Positive
Positive
Intervention
F Fiig gu ur re e   1 1. . The algorithm of the evaluation of abnormal aminotrans-
ferase levels in recipient and donor prior to alloHCT
Table 1. Early and late hepatic complications of allogeneic
hematopoietic cell transplantation
1 1. .   E Ea ar rlly y   C Co om mp plliic ca at tiio on ns s
Transient transaminitis
Drug toxicity
Sinusoidal obstruction syndrome
Acute graft-versus-host disease
Infections
Sepsis
Biliary problems (cholestasis, sludge, stone, obstruction)
2 2. .   L La at te e   C Co om mp plliic ca at tiio on ns s
Chronic viral hepatitis
Chronic graft-versus-host disease
Iron overload
Drug-related hepatotoxicity
Infections 
Sepsis
Biliary problems (sludge, stone, obstruction)
Cirrhosis and its complications
Hepatic malignancy
The presence of elevated transaminase levels prior to transplantation
The presence of pre-existing liver disease: HBV-, HCV-related liver disease
Recipients with liver metastases
Prolonged use of broad-spectrum antibiotic or anti-fungal drugs 
Intensive conditioning regimen use
Prior abdominal radiation therapy
Mismatched or unrelated donor transplant
Re-transplantation
Table 2. Pre-transplant risk factors that may be related with
development of post-alloHCT liver abnormalitiesclinical problem. However, the majority of these liver tests 
abnormalities do not indicate serious liver disease. The etiology
of mild-to-moderate serum aminotransferase elevations varies
depending on patient selection and geography. For example,
hepatitis B and C are common causes of elevated serum 
aminotransferases in Eastern European countries, whereas 
hepatitis C, alcohol-related liver disease, hepatic steatosis and
drug-induced liver disease are the most common causes in
Western countries.
Before extensive evaluation of abnormal aminotransferase 
levels, these tests should lead to retesting. The evaluation of
mild-to-moderate serum aminotransferase elevations should be
guided by the history, physical examination and nature of test
abnormalities (Figure 1). All individuals with abnormal 
aminotransferase levels should be advised to discontinue all 
medications if possible and abstain from alcohol. A liver biopsy
should be considered in individuals with persistent abnormal
aminotransferase levels prior to transplantation. 
For the assessment of HBV infection, an assessment of
hepatitis B surface antigen (HBs-Ag) positivity and hepatitis B
surface antibody (anti-HBs) and core-antibody (anti-HBc IgG)
positivity should be performed (Figure 2). Some centers also test
for the presence of HBV-DNA, especially in cases that are 
anti-HBc-Ab positive, to identify occult HBV infections. HBs-Ag
positivity identifies both asymptomatic carriers and those with an
active infection. Hepatitis B e-antigen (HBe-Ag) positivity helps to
distinguish between asymptomatic carriers and those with 
active infections in the absence of HBV-DNA data. HBV-DNA
detection using polymerase chain reaction (PCR) documents 
active viral replication. Liver biopsy should be performed prior to
transplantation in all HBs-Ag-positive recipients to assess the
severity of the hepatic inflammation and the stage of the 
disease. Liver biopsy in cases of isolated HBc-Ab positivity is 
recommended to identify the presence of active disease, the
current stage of the disease, and to determine whether the liver
is HBV-DNA positive or negative. 
When active HBV infection is identified, antiviral therapy must
be initiated prior to alloHCT (Figure 2). Although several anti-viral
agents are effective in reducing HBV viral replication, lamivudine,
a reverse-transcriptase inhibitor of the HBV-DNA polymerase,
has been used most widely [7]. Numerous studies have shown
that lamivudine treatment of chronic hepatitis B results in clinical,
biochemical and serological resolution of the HBV infection in 
immunocompetent individuals [7,8]. It is a remarkably safe drug
with only rare adverse events. Unfortunately, the efficacy of 
long-term lamivudine treatment decreases progressively as a 
result of the emergence of mutant lamivudine-resistant HBV
strains. In these cases, lamivudine plus adefovir can be utilized.
Although lamivudine suppresses HBV replication within two 
weeks of initiation of therapy, both agents should be continued
for several years and possibly indefinitely post-transplantation.
Hepatitis B infection in the donor: There is indisputable
evidence that HBV infection can be transferred from donor to 
recipient [9]. The risks of using a HBV-infected donor depend on
the HBV status of both the donor and the recipient. If the donor
is HBV-DNA positive, the approach should be the same as that
utilized in a HBV-positive potential recipient (Figure 3). The risk of
severe hepatitis in recipients who become infected with HBV
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F Fiig gu ur re e   2 2. . The management of HBs-Ag-positive recipient undergoing
alloHCT
HB-Ag-positive recipient
Inactive HBV
carrier
Chronic
Hepatitis B
Prophylaxis with
lamivudine
Treat with
lamivudine
Start lamivudine
prophylaxis
Normal ALT,
undetectable
HBV-DNA
Proceed with Transplantation
AFTER TRANSPLANTATION
Evaluate liver test (ALT)
HBV serology (HBe-Ag, HBV-DNA)
and underlying liver diease (liver biopsy)
Replicative Non-replicative
Monitor serum ALT level
Increased serum ALT and the presence of detectable HBV-DNA
Consider treatment with other anti-viral agents
Evaluate potential
naturally immune (anti-
HBs +, antiHBc lgG+) or
(anti-HBs +) donor
F Fiig gu ur re e   3 3. . The management of HBs-Ag-positive donor who is candidate
for donation
HB-Ag-positive donor
Inactive HBV
carrier
Chronic
Hepatitis B
Treat with
lamivudine
Start lamivudine prophylaxis in recipient
AFTER TRANSPLANTATION
Evaluate liver test (ALT)
HBV serology (HBe-Ag, HBV-DNA)
and underlying liver diease (liver biopsy)
Replicative Non-replicative
Monitor serum ALT level
Increased serum ALT and the presence of detectable HBV-DNA
Consider treatment with other anti-viral agents
Consider naturally immune
(anti-HBs +, antiHBc ›gG+)
or HBV vaccinated (anti-
HBs +) recipient
Normal ALT,
undetectable HBV-DNA
(non-replicative phase)from a donor ranges from 5 to 15% [2,10]; however, the risk of
transmission is less from a donor who is only anti-HBc IgG 
antibody positive, but can still be substantial and severe if the 
alloHCT recipient is HBV-naive. In a case controlled study 
performed by Lau et al. [11] comparing the clinical and 
serological outcomes of recipients receiving donor marrow from
HBV-positive or -negative donors, the occurrence of HBV-related
hepatitis in the recipient of a HBs-Ag-positive marrow was 
substantial [11]. In contrast to this result, in the experience at our
Bone Marrow Transplantation Unit, HBV-related hepatitis did not
occur in the naturally HBV-immune recipients who received stem
cells from inactive HBV carriers [12]. Based on these results,
inactive HBV carrier donors can be used for alloHCT donation if
the recipients of marrow have naturally acquired or active 
immunization-induced acquired HBV immunity.
The prevalence of HCV infection in individuals with 
hemato/oncological malignancies who undergo alloHCT varies
widely depending upon the HCV seroprevalence of the study
population. Because HCV infection in alloHCT recipients always
results in a chronic hepatitis [2,4,9], it is important to identify the
presence of an infection prior to transplantation to prevent the
development of post-transplant HCV-related liver morbidity and
mortality. Negative anti-HCV serological testing prior to alloHCT
is adequate to exclude the presence of a HCV infection in 
potential recipients of alloHCT. However, Locasciulli et al.[13] 
recommended that HCV-RNA testing be done as well. A liver 
biopsy should be obtained in all HCV-positive individuals 
regardless of the aminotransferases levels, as they have been
documented to have no relationship with the severity of the 
histological findings in a given individual. Although there is no
consensus regarding the pre-transplant treatment of a HCV 
infection in a HCV-positive individual who is candidate for 
alloHCT, it is recommended that if possible, HCV-positive 
individuals should be treated and the alloHCT be delayed until
the individual is in a non-replicative phase with normal 
aminotransferases levels and undetectable HCV-RNA in serum.
Hepatitis C infection in the donor: The transmission of a
HCV infection from a HCT donor who is HCV-RNA positive to a
recipient who is anti-HCV negative is essentially universal [2,4,9].
Recipients of such marrows become viremic with high viral load
within days of their alloHCT. No immediate HCV-related 
morbidity is observed, but with very high viral loads, a unique
form of HCV-positive liver disease, termed fibrosing cholestatic
hepatitis, can occur. This form of HCV disease is rapidly 
progressive and results in liver failure in less than a year. The 
more usual situation is that a chronic hepatitis C infection and 
clinical liver disease are seen only several months post-
transplant and progress to cirrhosis over 3-5 years [4,9]. 
Therefore, HCV-positive donors of HCV-naive recipients should
be delayed until the donor becomes HCV-RNA negative as a 
result of anti-viral therapy. It is important that the antiviral therapy
used be discontinued at least one week prior to stem cell 
donation to avoid subsequent engraftment problems in the 
recipients as a result of the anti-proliferative, myelosuppressive
effects of the anti-viral therapy used. 
B- Post-transplant evaluation
Liver test injuries are commonly seen after alloHCT (Figure 4).
Determination of the cause of these injuries is helped by the fact
that some liver diseases tend to occur within certain intervals 
following alloHCT. 
Regiment-related hepatotoxicity
The type of conditioning regimen prior to alloHCT plays a 
critical role in the development of early hepatic complications 
occurring as a result of the development of a hepatic venous
obstructive disorder (VOD), currently renamed the sinusoidal
obstruction syndrome (SOS) or drug-induced hepatic injury.
Sinusoidal Obstruction Syndrome (SOS): The most se-
rious early hepatic complication of HCT is SOS. This process 
represents a unique form of conditioning regimen-related 
hepatotoxicity. This condition occurs in 20% to 54% of HCT 
recipients [3,14-16]. SOS occurred in approximately 4.2% of 
alloHCT recipients in our Stem Cell Transplantation Unit 
between 1995 and 2005 (Unpublished experience). Historically,
the term VOD has been used to describe a clinical syndrome of
tender hepatomegaly, fluid retention, weight gain and the 
development of an increased serum bilirubin level as a result of
obliterative fibrosis and occlusion of small hepatic venules 
occurring due to a prior conditioning regimen. With the recent 
recognition that the vascular injury is initiated in the hepatic 
sinusoid, the name of this syndrome has been changed to SOS. 
The clinical onset of SOS is typically recognized by day +20 
after alloHCT. However, later onsets of this process have been 
reported [3,6]. Between 10-20 days after the initiation of the 
conditioning regimen, an increase in liver size, right upper 
quadrant abdominal tenderness and weight gain occur followed
by hyperbilirubinemia. Patients with SOS manifest findings 
consistent with a diagnosis of the hepatorenal syndrome with 
intense sodium avidity, portal hypertension and multiorgan failure.
SOS can range in severity from a mild reversible disease process
to a severe syndrome associated with multiorgan failure and 
death [3,6,14-15]. 
Injury to the sinusoidal endothelial cells and hepatocytes in 
zone 3 of the liver acinus appears to be a critical process in the 
development of SOS. In vitro studies have demonstrated that 
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F Fiig gu ur re e   4 4. . Diagnostic evaluations of recipients with hepatic injury after alloHCT
Abnormal liver tests
Hepatocellular Injury Cholestatic Injury Mixed Pattern
Viral hepatitis GVDH Viral hepatitis
Dug-toxicity Drug-toxicity GVHD
Raley, GVHD SOS Drug-toxicity
Biliary problems Raley, SOS
Spesis
CMV-hepatitissinusoidal endothelial cells are more susceptible than hepatocytes
to drug-induced toxicity [3,16]. The use of drugs such as 
cyclophosphamide (CY) and busulphan (BU) in the conditioning
regimen prior to transplantation with/without total body 
irradiation (TBI) have been implicated most often in the 
development of SOS [3,6,14,15]. Based on the evidence 
obtained from animal and clinical studies, the drugs that have
been recognized to cause SOS deplete glutathione in sinusoidal
endothelial cells as well as hepatocytes [3,6,14,15]. CY and its
metabolites (acrolein) are the primary sinusoidal toxin in 
individuals conditioned with CY-based cytoreductive therapy
[17]. BU produces liver injury by inducing oxidative stress, 
reducing sinusoidal endothelial cell glutathione levels, which 
interferes with CY metabolism [18]. There is also a clear 
relationship between the total dose of TBI administered during
marrow conditioning and the frequency of SOS [3,17,19], but no
strong relationship exists between the irradiation techniques
used and the subsequent development of SOS [3,19]. A 
synergism exists between the amount of TBI and the dose of CY
that leads to development of sinusoidal injury and of SOS
[3,16,19]. It is well known that depletion of glutathione in 
sinusoidal endothelial cells and hepatocytes by CY leaves these
cells more vulnerable to irradiation-induced injury [3,16,19]. A 
randomized study has documented a greater incidence of SOS
in individuals receiving BU plus CY as compared to a CY and TBI
conditioning regimen [20]. Other risk factors for the development
of SOS include older recipient age, female gender, poor 
performance status, advanced primary disease, prior radiation,
prior exposure to vancomycin or amphotericin B, elevated 
aminotransferases levels (AST > 4 times upper limit of normal) 
prior to the conditioning regimen, use of a HLA- mismatched and
unrelated donor, and second transplant procedure 
[3,14,15]. SOS occurs less frequently when peripheral blood
stem cells are used as compared to the bone marrow derived
stem cell [14]. The reasons for this latter observation are unclear. 
As noted, the clinical diagnosis of SOS is based on 
the presence of a triad consisting of weight gain, painful 
hepatomegaly and jaundice. Measurement of the total serum 
bilirubin level is a sensitive procedure for the detection of SOS but
it is not specific, as many causes of jaundice exist after alloHCT.
Elevations in serum aminotransferase levels can occur in the 
course of SOS and reflect the degree of ischemic hepatocyte 
injury. The diagnostic criteria for SOS proposed by the Seattle
[21] and Baltimore groups [22] have a specificity of 91 to 92%,
but a rather low sensitivity. Both of these proposed criteria 
included hyperbilirubinemia (>2 mg/dl within 21 days of alloHCT)
and at least two of the following: hepatomegaly, weight gain
(>5% from baseline), and presence of ascites. Imaging studies of
the liver (ultrasound and tomography) are useful for 
demonstrating hepatomegaly, ascites and attenuated hepatic 
venous flow consistent with SOS as well as in excluding other
causes for these findings. Transvenous liver biopsy and wedged
hepatic venous pressure gradient (HVPG) measurements remain
the gold standards for a diagnosis of SOS. An elevated HVPG
(>10 mmHg) is highly specific (90%) and moderately sensitive
(60%) in establishing a diagnosis of SOS, and importantly, 
identifies individuals with a poor prognosis [23]. 
No treatment strategies for SOS have been proven to be 
effective in the prospective, randomized, controlled studies
[2,3,14,15]. Various prophylactic treatment modalities have 
been proposed that have focused on reducing the glutathione
depletion occurring with conditioning. Other therapies act by
modifying inflammatory mediators and altering the coagulation
and fibrogenesis process. SOS is fatal in approximately 7% of 
individuals with the syndrome with no identifiable risk factors
who have received a CY-based conditioning regimen following
CY/TBI and in 5% of individuals following targeted oral BU and CY
conditioning [24]. CY-based regimens are more likely to result in a
SOS mortality in individuals who come to alloHCT with other risk
factors that include hepatic fibrosis, chronic hepatitis C, 
nonalcoholic steatohepatitis and any infection before the start of
the conditioning regimen [2,3,25]. The relative risk of a fatal SOS
is approximately 10-fold higher in individuals with chronic 
hepatitis C as compared to individuals without any pre-existing 
liver disease [25]. 
Several approaches have been utilized to prevent a 
SOS-associated fatality. These are: first, to avoid higher doses of 
conditioning regimen; second, to monitor the levels of the drugs
being used, minimizing drug-induced hepatic damage; and
third, to use a nonmyeloablative regimen that is not recognized
as producing hepatotoxicity. 
A number of randomized trails have examined the effect of
anticoagulation therapy in preventing SOS. Only one study 
conducted in low-risk patients has demonstrated a beneficial 
effect of heparin prophylaxis [26]. 
The prophylactic administration of ursodeoxycholic acid 
(UDCA) to prevent or reduce the severity of SOS has been 
studied in a number of randomized placebo controlled 
prospective studies [2,3,27-29]. Some of these have reported a
reduced severity of SOS with UDCA therapy. The incidence of
SOS in two older studies was reduced to 3% and 15% in the
UDCA-treated groups as compared to values of 19% and 40%
in the control groups [27,28]. However, a large randomized
Scandinavian study failed to demonstrate any benefit of UDCA
therapy [29]. Nonetheless, some transplant centers use UDCA
routinely in an effort to reduce the severity and frequency of
SOS. The effect of hepatic glutathione supplementation has 
been examined in experimental models, but it has been difficult
to find a clinical rational for these findings. Currently, in our
Transplantation Unit, we are not using a routine prophylactic 
medication in an effort to prevent or reduce the severity of SOS. 
Because the precise pathogenesis of SOS remains 
unclear, no completely satisfactory treatment exists. The 
current treatment of SOS consists of minimizing any exposure
to recognized hepatotoxins and avoiding nephrotoxins, the use
of analgesia for pain, limiting the individual’s intake of sodium,
diuresis and/or paracentesis, and the correction of any coagu-
lopathy. Renal and pulmonary failure in individuals with severe
SOS is managed with hemodialysis and mechanical ventilation. 
Drug-induced hepatotoxicity: Drug-induced hepatotoxicity
in the first week following alloHCT is probably more common than
appreciated. Fortunately, severe liver damage due to drugs during
this period is rare. In the pre-transplant and early post-transplant
periods, patients receive a multitude of drugs, including the drug
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methotrexate (Mtx), antibacterial, antifungal, and antiviral agents
and various growth factors [2-3,6]. Total parenteral nutrition (TPN)
is often implicated in the production of mild elevations of cholesta-
tic enzymes as well as the level of bilirubin and aminotransferases
in the serum. Liver biopsy is not particularly helpful in establishing
a drug-induced hepatotoxicity, but is important in excluding other
causes of liver disease such as SOS, aGVHD and sepsis.
Infections 
Infections significantly contribute to the complications 
associated with alloHCT [2,6,30,31]. The particular type of 
infection at a given time is a function of the time after alloHCT. 
Before engraftment, bacteria are the most common pathogens and
rarely involve the liver. Immediately after engraftment, viral 
infections become the principal agents responsible for infection [31]. 
The depressed T-cell mediated immune response occurring
post-alloHCT persists for a period ranging from several months
to more than a year and is a consequence of the underlying 
primary hematological disease process, the requirement for 
conditioning chemotherapy/radiotherapy, and the drugs used
for infection prophylaxis and the treatment of GVHD [31-33]. The
presence of specific antibodies such as anti-HBs is important in
preventing infections with viruses, and loss of these antibodies
over time after alloHCT enhances the risk of re-infection with vi-
ruses which the recipient had pretransplant exposure, prior to
the alloHCT [31]. Reconstitution of an effective immune system
following alloHCT plays an important role in the 
subsequent defense against viral infections [32,33]. 
Hepatitis B virus infection
The median prevalence of HBs-Ag-positive individuals 
requiring HCT has been reported to be 1% in American 
recipients, 3.5% in European recipients and 9% in Turkish 
recipients [34-36]. HBV infection in alloHCT recipients occurs in
different ways; the progression of pre-transplant primary active
disease, activation of a latent HBV infection or acquisition of a de
novo HBV infection [3,6]. As a result of the immunosuppressive
therapy required pre- and post-alloHCT, the HBV viral load 
increases in both the liver and blood of the HBV-positive 
recipient. This continues until either immune reconstitution 
occurs or the immunosuppression being used is reduced. A 
clinical flare-up of hepatitis (elevations in aminotransferases and
the presence of jaundice) may be seen at the time of cellular 
immune reconstitution. This response can distinguish between
viral hepatitis and other causes of liver abnormalities such as
GVHD seen post-alloHCT. A positive serum HBV-DNA assay is
required to diagnosis and/or to confirm HBV infection. Anti-viral
therapy should be used if a diagnosis of HBV is established as a
result of a positive HBV-DNA test. The most appropriate 
treatment strategy and the dose and the duration of the HBV 
anti-viral therapy are unknown. The risk of fatal HBV-induced 
liver disease in an alloHCT recipient that is HBV-DNA positive is
approximately 15% without specific anti-HBV therapy [2,9]. 
HBV Vaccination: The adoptive transfer of immunity to HBV in-
fection can be accomplished in bone marrow transplantation (BMT)
recipients from donors who are either naturally immune or have 
received active HBV immunization prior to donation [12,37]. In 
such cases, bone marrow-derived memory cells, capable of 
producing antibodies to the HBV envelope and/or nucleocapsid 
antigens, are transferred from the donor to the recipient [12,37]. This
phenomenon prevents new HBV infections and can lead to the 
clearance of a pre-existing HBV infection in the recipient of stem cells
from an anti-HBV-positive donor [12,37]. 
An experience of 16 allo-peripheral blood cell transplantation
(PBCT) recipients and their donors, who were vaccinated 
against HBV at a dose of 40 mg administered for three 
consecutive months, has been reported [38]. Eighty-eight 
percent of these recipients seroconverted to anti-HBs antibody po-
sitivity (>10 mIU/ml). This rate of seroconversion (88%) in PBCT 
recipients is comparable to that reported by Ilan et al. [39] in BMT
recipients and by Nagler et al. [40] in autologous BMT 
recipients. None of the HBV vaccinated recipients had either 
clinical or serological evidence of HBV-related hepatic events du-
ring the conditioning regimen or post-transplant follow-up 
period. Based on this experience, the vaccination of both HBV-nai-
ve recipients and donors results in the development of an effective 
antibody response to HBV infection in the alloHCT recipient. 
The durability of this vaccine-induced immunity in alloHCT 
recipients, however, is not clear. Most transplants lose their 
immunity after transplantation. In the experience cited above
[38], a substantial proportion of the HBV-vaccinated recipients
(57%) lost their immunity over a period of time (a median of
236.2 days). Nagler et al. [40] reported that 37% of their HBV 
antibody-positive recipients lost their immunity within 17-45 days
of transplantation as a result of defective immune reconstitution.
Thus, systematic re-immunization is necessary following 
transplantation to maintain HBV immunity.
Immunity against HBV infection can be transferred from an
anti-HBs-positive donor to a recipient of alloHCT [12,38-40].
Wimperis et al. [41] showed that immunization of the donor 
alone results in transfer of an antibody response to the recipient
after T cell-depleted BMT. In our own experience [38], 83% of
HBV-naive recipients with an HBV-immune donor seroconverted
to anti-HBs antibody positivity after transplantation. In addition,
two HBs-Ag- positive recipients having a HBV-immune donor 
seroconverted to anti-HBs antibody positivity after transplantation.
Lau et al. [37] reported that 10% of the recipients with chronic
hepatitis B who had an anti-HBs-positive donor sustained HBV
clearance after alloBMT. The rate of seroconversion observed in
these studies is higher than that reported as a consequence of
either spontaneous resolution or as a result of anti-viral therapy.
None of the HBs-Ag- positive recipients with HBV naive donors
in each of these studies cleared HBV. These findings suggest
that adoptive transfer immunity works not only in HBV-naive 
individuals, but also in HBV-infected individuals. Clearly, the HBV
immune status of the donors plays an important role in 
seroconversion of recipients following alloHCT.
On the other hand, HBV-naive recipients of HBV-naive donor
stem cells continue to be at risk for HBV infection in the 
post-transplant period. In our own experience [38], one HBV-
naive recipient developed an active de novo post-alloHCT HBV
infection and three others developed an asymptomatic HBV 
infection manifested by seroconversion to anti-HBs and 
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suggested that HBV-naive recipients should either be 
vaccinated against HBV or receive stem cells from an anti-HBs-
positive donor. 
HBV Reactivation: Reactivation of HBV infection is a well-
recognized complication of immunosuppressive therapy in 
individuals who are HBs-Ag-positive inactive carriers or those
with recognized chronic HBV infection as well as those with an
occult HBV infection [9,42,43]. Reactivation of HBV infection 
occurs in 14% to 50% of such individuals [9,42,43]. The 
mortality associated with viral reactivation varies between 3.7%
and 60% [2,9,42,43]. Several factors contribute to the 
development of viral reactivation in HBV carriers receiving 
chemotherapy [42,44,45] (Table 3). HBV infection after organ
transplantation can occur because of either reactivation of a 
latent endogenous HBV infection or acquisition of HBV infection from
the donor or acceptance of contaminated transfused 
blood and blood products [2,3,6]. Such HBV infections have 
been associated with rapid liver disease progression to liver decom-
pensation and even fulminant hepatic failure and death [2,3,6] 
Lamivudine used as prophylaxis of HBV reactivation 
Lau et al. [35] evaluated the efficacy of lamivudine to prevent
recurrent HBV-related hepatitis in alloHCT recipients. Only one
recipient given lamivudine experienced HBV reactivation after
transplantation. In contrast, 45% of the individuals in the control
group experienced HBV reactivation and 15% of these 
individuals experienced HBV-related hepatic failures [35]. The
authors concluded that preemptive lamivudine therapy reduced
the HBV reactivation rate in HBV-positive recipients after 
alloHCT and improved survival [35]. Seven HBs-Ag-positive 
alloHCT recipients who did not receive anti-viral prophylaxis 
were reported in 1999 [12]: one died 30 days post-transplant
because of HBV-induced fulminant hepatic failure. HBV-induced
chronic active hepatitis occurred in three [12]. Based on these
results, lamivudine prophylaxis in HBV-positive recipients 
undergoing alloHCT appears to prevent immunosuppressive-in-
duced HBV-related post-alloHCT morbidity and mortality and
has become the standard of therapy.
The optimal duration of lamivudine prophylaxis in alloHCT 
recipients at risk for HBV reactivation has been investigated [46].
Unfortunately, there are no clear data in the literature to 
indicate how long prophylactic lamivudine therapy should 
be continued in HBV-positive recipients who continue to receive 
immunosuppression. Long-term (>1 year) antiviral therapy is 
required to eradicate HBV infection in immunocompetent 
individuals because of the high rate of HBV replication (plasma
half-life of HBV, 24 hours) and the relatively slow turnover rate of
HBV-infected hepatocytes (half life, 10-100 days) [7,8,46]. 
Lamivudine produces a rapid reduction in HBV replication within
days of its initiation [7,8]. In immunosuppressed subjects, several
investigators have suggested that lamivudine treatment in cases
of inactive HBV infection should be continued for at least the 
duration of the immunosuppression and possibly longer
[7,35,46]. Based on the experience in liver transplantation, 
long-term lamivudine prophylaxis in alloHCT recipients at risk for
HBV reactivation seems reasonable.
The adverse effect profile of lamivudine does not overlap with
that of the various immunosuppressive agents used in 
transplantation [35,46]. No hematological abnormalities, hepatic
enzyme flares or reductions in immunosuppression dosage have
been reported as a result of lamivudine in previous studies of 
transplant recipients.
The risk of developing lamivudine-resistant HBV increases
with the duration of lamivudine treatment [7]. Most cases of 
resistance are associated with mutations in the YMDD motif of
the HBV polymerase gene [7]. Resistance rates between 15%
and 40% have been reported after two years of 
lamivudine treatment in immunocompetent individuals [7]. In 
immunosuppressive individuals, Chan et al. [47] reported a 
cumulative resistance rate of 41% after 31 months in HBs-Ag-
positive kidney allograft recipients. Lau et al. [35] reported a 
single alloHCT recipient (1/20) case treated with lamivudine who
developed lamivudine resistance after 40 weeks of therapy. 
The development of HBV resistance has been a limiting 
factor in the durability of lamivudine treatment. Adefovir dipivo-
xil, a monophosphate nucleotide analogue approved by the
United States Food and Drug Administration, represents the
newest approach to the treatment of HBV infection [48]. In
contrast to lamivudine, viral resistance to adefovir as a result of
prolonged therapy occurs at a 3-4-fold reduced rate in immu-
nocompetent individuals [48]. Moreover, adefovir is effective
against mutant HBV lamivudine-resistant virus. There are no
data available concerning the efficacy, safety and tolerability of
adefovir dipivoxil when used to treat lamivudine-resistant HBV
reactivation in alloHCT individuals. Additional studies are requi-
red to clarify the precise role of adefovir dipivoxil (or other nuc-
leos(t)ide analogues) in immunosuppressed individuals in order
to clearly define its efficacy and to identify potential adverse he-
matological side effects of its use. 
Hepatitis C virus infection
Unlike HBV infection, HCV-related hepatitis is unusual in 
alloHCT recipients. Post-transplant HCV infections in alloHCT 
recipients may arise in two ways: progression of pre-transplant
HCV infection or acquisition of a de novo HCV infection from 
either a HCV-infected donor or via having accepted a 
transfusion of HCV-infected blood and blood products [2,3,6,9].
A minimal increase in liver-related mortality in the first 10 years as
a result of a HCV infection has been reported after alloHCT [3,9].
Asymptomatic mild to moderate transaminitis not exceeding a
level of 300 U/L is seen frequently in the post-transplant period
of HCV-positive alloHCT recipients and coincides with the 
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Table 3. Factors predisposing to HBV reactivation in HBV 
carriers who receive chemotherapy
1 1. .   H Ho os st t- -r re ella at te ed d
Primary hemato/oncological disease (lymphoma)
Preexisting liver disease
Young age
Male gender 
2 2. .   V Viir ru us s- -r re ella at te ed d
High serum HBV-DNA levels
3 3. .   T Tr re ea at tm me en nt t- -r re ella at te ed d
High dose of chemotherapy
Corticosteroid treatment tapering of the immunosuppressive drugs used to prevent
GVHD. During this time, it may be difficult to determine whether
a flare of hepatitis C or GVHD is responsible for the observed 
increase in serum transaminase values. Differentiation of these
two disorders, however, is crucial for appropriate therapy. HCV-
RNA detection using PCR documents active viral replication. A
liver biopsy should be obtained before any specific therapeutic
decision is made. 
With longer periods of observation, HCV-induced cirrhosis is
emerging as an important late complication of alloHCT. It can 
result in liver failure and HCV-induced hepatocellular carcinoma.
In contrast to the 20-40 year period of HCV-induced liver 
disease experienced in immunocompetent individuals, HCV-
related liver disease in alloHCT recipients runs an accelerated
course to cirrhosis that can occur as soon as 4-5 years 
post-transplantation. 
The reported sustained response rates to combination 
anti-viral therapy (interferon (IFN) plus ribavirin) in alloHCT 
recipients with HCV infections are similar to those 
reported in immunocompetent individuals [2]. IFN therapy is 
contraindicated in the early post-transplant period 
because of its myelosuppressive effects and the possibility of 
inducing or exacerbating GVHD. HCV-positive recipients 
should be evaluated for anti-viral therapy after all of their 
immunosuppressive therapy has been discontinued and there is
no current evidence of GVHD. The combination of pegylated
(PEG)-IFN and ribavirin therapy should be used in the treatment
of HCV-induced hepatitis in alloHCT recipients, but it needs to
be administered carefully with particular attention to its 
myelosuppressive effects. 
Fungal liver infection
Fungal infections usually occur in the first weeks post-trans-
plant and in recipients treated for GVHD or in those with primary
disease activation, in whom they can occur at any time [3,6]. 
Candida albicans is the most frequently identified fungal pathogen
in alloHCT recipients [3,6]. Hepatic and splenic abscesses are 
a common presentation in such cases. Hepatic involvement 
usually occurs in the context of a systemic disease process, 
although isolated hepatic involvement has been reported. The 
clinical presentation of hepatic candidiasis consists of tender 
hepatomegaly, persistent fever and elevated serum alkaline
phosphatase levels. 
The prophylactic use of fluconazole has virtually eliminated
hepatic candidiasis in alloHCT recipients. The incidence of 
candida infections in older series has been reported to be as
high as 28%. With fluconazole prophylaxis, the incidence of this
infection has declined to 7% [3,49]. Unfortunately, with 
fluconazole prophylaxis, an increase in the incidence of 
infections with candida species other than Candida albicans has
occurred [3]. These non-albicans species are resistant to 
fluconazole and other agents need to be utilized for their s
uccessful treatment. 
A specific diagnosis of a fungal infection is critical when it 
occurs, as systemic anti-fungal therapy before and during 
alloHCT is mandatory. A raised alkaline phosphatase is 
suggestive but non-specific for the diagnosis. The most 
sensitive imaging modality is magnetic resonance imaging. 
Serological tests such as fungal antigen detection and 
determination of fungal DNA in serum may be useful. It is 
important to clearly identify the specific pathogen. This often 
requires a liver biopsy with a culture of the liver tissue. The 
choice of subsequent anti-fungal therapy needs to be tailored to
the specific fungal species isolated and its sensitivity to the 
available anti-fungal drugs. AlloHCT recipients with disseminated
disease need to be treated aggressively for a prolonged period.
Restoration of granulocyte counts is critical to their recovery and
may require the use of granulocyte colony-stimulating factor. 
Graft-versus-host disease
GVHD is a major complication of alloHCT and contributes
substantially to the overall transplant-related morbidity and 
mortality [50,51]. Both acute (aGVHD) and chronic GVHD (cGVHD)
affect the skin, liver and gut [50,51]. Because the histological 
findings of GVHD are non-specific, diagnosis often requires the 
utilization of both clinical and histological criteria [50,51]. 
aGVHD of the liver develops within 2 to 10 weeks of alloHCT
and occurs in approximately 40-60% of HLA-identical 
transplants [2,3,6,50,51]. aGVHD occurred in approximately
30% of alloHCT recipients in our Transplantation Unit between
1995 and 2005. Liver involvement usually occurs in 
association with skin and intestinal GVHD. The liver dysfunction 
associated with aGVHD is primarily a cholestatic pattern and is 
characterized by an elevation of serum alkaline phosphatase, 
bilirubin and to a lesser extent the aminotransferases levels. 
However, it needs to be remembered that transaminase levels
can be markedly elevated (up to 10 times of normal) in aGVHD.
In contrast, in cGVHD, these same liver injury tests are usually
only slightly increased. The hepatic manifestation of GVHD can
present with nausea, vomiting, abdominal pain, and massive 
diarrhea with/without blood. The cholestasis in aGVHD can 
range from a mild biochemical disease process to overt 
jaundice. Moderate to marked elevations in the serum alkaline
phosphatase level are usual and precede hyperbilirubinemia. 
Although elevations in serum alkaline phosphatase have been
proposed as a sensitive identifier of GVHD, progressive jaundice
is the most common presenting feature [3]. In alloHCT 
recipients, aGVHD can present as an acute hepatitis with serum
aminotransferase levels over 1000 IU/L during the tapering of the
immunosuppressive therapy being utilized to enable successful
engraftment [50,51]. Features of severe hepatocellular 
dysfunction are terminal manifestations of liver disease seen in 
individuals with severe multisystem GVHD. 
Although a liver biopsy is usually not necessary to establish a
diagnosis of aGVHD when the other clinical findings of aGVHD
are present, it may be required to establish the diagnosis of 
isolated hepatic GVHD and to rule out the other etiologies for the
observed liver abnormalities, such as acute viral hepatitis, SOS,
drug toxicity or sepsis. The histologic findings of hepatic aGVHD
depend upon when in the course of the disease the biopsy is 
obtained [3,6,50,52]. In the early phase, the findings are 
characterized by a mixed lymphocytic and eosinophilic 
infiltration of small bile ducts with nuclear pleomorphism, 
minimal lobular inflammatory infiltrates and bile duct 
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scattered acidophilic bodies, lobular disarray and cholestasis
may be present. The extent of these abnormalities varies with
duration of the aGVHD. In the later phase, there is destruction of
small bile ducts accompanied by ductular proliferation and an 
endothelialitis affecting the terminal hepatic veins. This 
endothelialitis is a relatively specific feature of GVHD [3,6,50,52].
Treatment of aGVHD of the liver usually involves the addition
of methylprednisolone (MP) at a dose of 2 mg/kg/day to the 
existing immunosuppressive regimen [3,6,50]. Treatment with
doses greater than 2 mg/kg/day does not improve the 
response rate but does increase the rate of infectious 
complications. In a large retrospective study [53], the liver 
abnormalities associated with GVHD improved in only 30% of
the individuals with aGVHD [53]. There is no proven second-line
treatment for steroid-refractory aGVHD, including the use of 
tacrolimus or antithymocyte globulin. The prognosis is poor if
steroids fail to control aGVHD because secondary treatment 
regimens induce disease control in only a minority of the cases
so treated [2,3,6]. 
cGVHD of the liver is a complex multisystem disorder that
develops at or after day +100 post-alloHCT [2,3,6,50,54,55]. It
is usually seen with other manifestations of cGVHD such as dry
eyes, oral mucositis, and a scleroderma-like skin disease. The
incidence of cGVHD after alloHCT ranges from 27% to 72% 
[2,3,6,50,54,55]. Liver involvement is reported in 73% to 86%
[2,3,6,50,54,55]. cGVHD occurred in approximately 60% of 
alloHCT recipients in our Stem Cell Transplantation Unit 
between 1995 and 2005: 55% had limited stage cGVHD and
the remaining 40% had extensive stage cGVHD. 
cGVHD represents a manifestation of profound immune
dysfunction. In most of these cases, the deaths observed are a
result of an acquired infection [2,3,6,50,54,55]. cGVHD can 
either follow or progress from aGVHD or develop de novo in
20% of the cases [2,3,6,50,54,55]. The pathogenesis of cGVHD
is different from that of aGVHD. Although its precise 
pathogenesis remains unknown, cGVHD bears a resemblance
to a variety of immune-mediated autoimmune disorders. Several
B- and T-cell-mediated abnormalities have been described in
cGVHD. These include diminished T-cell responsiveness, 
decreased B-cell proliferation, impaired antibody production, a
reduced number and function of CD4+ cells, and an increased
number of CD8+ suppressor cells. The induction of increased
histocompatibility antigens and leukocyte adhesion molecule 
expression on tissues such as bile ducts identifies these cells as
the targets for the alloreactive donor T-cells. These CD8+ T-cells
proliferate and secrete inflammatory cytokines (IL-2, IL-1 and
TNF- α) which contribute to the tissue injury [2,3,6,50,54,56].
The clinical presentation of cGVHD of the liver is similar to
that of primary biliary cirrhosis (PBC). Specifically, the serum liver
injury tests reveal a cholestatic pattern with elevations of alkaline
phosphatase, at least 5-15 times the upper limit of normal, as
well as increased levels of GGT and bilirubin with or without an
increase in the serum aminotransferases levels. The increases in
the serum alkaline phosphatase and GGT usually precede the
development of jaundice by weeks to months. 
The diagnosis of cGVHD is made on the basis of combined
clinical and laboratory parameters. It is important to confirm the
diagnosis by liver biopsy and thereby exclude other possible 
liver diseases. The histologic criteria for cGVHD include the 
findings of bile duct damage and/or ductopenia with infiltration of
the smaller bile ducts with lymphocytes and eosinophils, portal
area expansion with both lymphocytes and plasma cells and the
presence of cholestasis [57,58]. 
The current system of grading cGVHD as either limited or 
extensive has severe limitations [57]. This grading system 
provides little information about prognosis; is of limited clinical
utility; and does not correlate well with either the degree of 
clinical manifestation or the extent of histopathological 
abnormalities. Several investigators have developed a revised
grading system for cGVHD [3,6,50]. Recently, Akpek [59] 
reported a new prognostic grading system for cGVHD. Using
this system, patients are categorized based on the presence or
absence of extensive skin involvement, thrombocytopenia and
progressive disease [59]. Shulman et al. [58] also developed a
histopathological grading system for hepatic cGVHD. Their 
histopathological grading system has a positive predictive value
of 86%, a sensitivity of 66% and a specificity of 91% [58,59].
Currently, there is debate as to which grading system is best.
Although various immunosuppressive drugs including CsA,
tacrolimus, Mtx, MP and mycophenolate mofetil have been used
to reduce the incidence and severity of cGVHD in alloHCT 
recipients [2,3,6,50], the results of such therapies have not 
been particularly successful. 
When a diagnosis of cGVHD has been made, the extent of
involvement must be ascertained. Because cGVHD can affect
virtually any organ system, the most successful treatment of
such recipients results when a systematic approach in 
discussing documentation and management is undertaken 
by a multidisciplinary team including transplant physicians, 
gastroenterologists, pathologists, dermatologists, pulmonolo-
gists and ophthalmologists. The specific treatment of cGVHD in
a given individual is determined in part by the severity of the 
disease process. First-line therapy consists of the 
administration of immunosuppressive agents [2,3,6,50]. The use
of immunosuppressive drugs (MP: 1 mg/kg/day, CsA: 10
mg/kg/day) is successful in 50-80% of cases [3,6,50]. Even with
widespread involvement, the institution of appropriate 
immunosuppression can result in a very gradual but complete
recovery. After the start of immunosuppressive therapy, a 
decline in the serum alkaline phosphatase level can be expected
within 2-4 weeks. It may not return to normal even if there is
complete improvement in other target organs. The immunosup-
pressive drugs used to treated cGVHD can be tapered and 
discontinued only after full resolution of the disease 
manifestations. Once this occurs, the dose of immunosuppres-
sive agents being used can be tapered at regular intervals. In
50% of cases with cGVHD, immunosuppressive treatment can
be discontinued after 9-12 months. If an individual with cGVHD
does not respond within three months of the institution of 
specific therapy or progresses while on therapy, an alternative
salvage regimen, such as the addition of CsA, tacrolimus,
mycophenolate mofetil or rapamycin, should be instituted
[3,6,50]. In some cases, liver transplantation can be used to 
treat cGVHD-induced end-stage liver disease. 
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UDCA is a hydrophilic, non-toxic bile acid that induces a 
choleresis [60]. UDCA constitutes less than 5% of the total bile
acids in normal bile. This can be increased to approximately
40% of the total bile acid pool by the oral administration of 
UDCA [60]. UDCA has been used successfully in the treatment
of a wide array of chronic cholestatic liver diseases such as PBC
and primary sclerosing cholangitis [60-62]. UDCA also has some
efficacy in the prevention of allograft rejection after liver 
transplantation [63]. The mechanisms responsible for the liver 
protective effects of UDCA are not completely understood but 
include stabilization of liver cellular membranes and its ability to 
stabilize HLA antigens deleting hepatocytes and bile duct 
expression of these antigens [60-62]. UDCA has also been shown
to reduce the secretion and action of various inflammatory 
cytokines such as interleukin-1 alpha (IL-1α), IL-2, IL-4, tumor 
necrosis factor-alpha (TNF-α) and gamma interferon [60,62]. 
In a prospective randomized open-label multicenter study, it
was reported that UDCA prophylaxis has a beneficial effect on
abnormal liver tests, reduces the incidence of severe aGVHD,
and improves patient survival [29]. UDCA prophylaxis may 
decrease transplantation-related hepatic complications of 
alloHCT, but further studies are needed to fully evaluate the 
effect of prophylactic UDCA in alloHCT recipients. 
UDCA has been used as treatment for several liver problems.
Fried et al. [64] reported that cholestasis secondary to hepatic
GVHD after alloHCT improves in 33% of patients treated with a
6-week course of UDCA therapy. However, a significant 
worsening of all liver test results occurs after discontinuation of
UDCA therapy. No data exist relative to the long-term effects of
UDCA therapy in cGVHD of the liver. In a prospective study [65],
the long-term effects of UDCA treatment in individuals with 
limited cGVHD of the liver following alloHCT were examined.
Specifically, 15 alloHCT recipients were treated with UDCA at a
dose of 13 mg/kg/day p.o. for one year. Nine of the 15 received
UDCA as a sole therapy for hepatic cGVHD. The remaining 6 
received UDCA along with a tapering dose of CsA. As 
compared to baseline values, all 15 patients experienced an 
improvement in their liver tests. The values for the mean serum
alkaline phosphatase, GGT and aminotransferase levels at one
year were all reduced statistically in those taking UDCA. No 
increase in serum liver enzyme levels was observed three
months after completion of UDCA therapy. Symptomatic 
improvement (pruritus resolved in 7 of 9 recipients) as well as a
biochemical response was observed after one year of UDCA
therapy [65]. Based on this experience, it was concluded that
the long-term administration of UDCA is effective in improving 
liver enzyme tests in patients with isolated cGVHD. 
Symptomatic improvement also occurred. Clearly, additional
studies in a larger group of patients, including those with other
manifestations of cGVHD, are warranted to evaluate the utility of
UDCA therapy.
UDCA is an easy drug to use. It is taken orally and has few
side effects. The most frequent UDCA adverse event is 
diarrhea, which is seen in less than 5% of individuals treated with
the agent [29,64,65]. No drug-induced cytopenias occur. 
Discontinuation of UDCA therapy in alloHCT recipients is not 
followed by an exacerbation of disease signs or symptoms. 
Iron overload
Iron overload is recognized as a common contributor to the 
liver abnormalities in the late post-transplant period. Hepatic 
hemosiderosis is found in approximately 90% of long-term 
survivors of alloHCT [3,66]. Hepatic hemosiderosis is caused by
a combination of multiple blood transfusions, especially in 
thalassemic patients, and dyserythropoiesis. Although many 
marrow transplant recipients have a high hepatic iron content 
50-100 days post-transplant, iron deposition stops and iron 
store falls slowly over time thereafter because transfusions are no
longer required as the primary hematological disease process
has been cured. 
The mechanisms of tissue injury that occur in iron overload
states have been investigated in several models [3,6,67]. One
hypothesis is that iron-induced lipid peroxidation occurs in 
hepatocytes causing cell injury and death. Kupffer cell activation
also occurs. These later cells produce profibrogenic compounds
that stimulate hepatic stellate cells to increase collagen 
production leading to fibrosis. Liver biopsy studies in alloHCT
candidates have documented a high prevalence of portal 
fibrosis, cirrhosis and hepatocellular carcinoma occurring in 
association with marked hemosiderosis [3]. In addition extreme
iron deposition in visceral organs results not only with 
hepatotoxicity but cardiac and endocrinological problems as
well. The risk of opportunistic infections that include Listeria and
Yersinia is increased in immunocompromised recipients with 
hepatic hemosiderosis as a result of an iron-induced reduction in
the generation of T cells and impaired T-helper, natural killer cell
and Kupffer cell function.
Because iron overload in alloHCT survivors can lead to 
multiple organ dysfunctions, all alloHCT survivors should be 
assessed for iron overload. It can be evaluated by measuring the
serum ferritin level, which is a reliable indicator of tissue iron 
stores. Computerized morphometric analysis of bone marrow
iron content is available for estimating the hepatic iron stores in
alloHCT recipients. A liver biopsy is required to accurately 
quantify hepatic iron content. 
Phlebotomy and/or chelation therapy with desferrioxamine
can be utilized to reverse excessive hepatic iron load and to 
improve hepatic as well as other organ (cardiac) function. Iron
depletion prior to transplantation may reduce post-transplant
hepatotoxicity especially in individuals with thalassemia.
Cholestasis
Cholestasis results from interference with bile flow anywhere
from the basolateral membrane of the hepatocyte to the entry of
the bile duct into the duodenum. 
Cholangitis lenta: Sepsis-associated cholestasis is a form of
biliary tract inflammation without obvious extrinsic bile duct 
obstruction and is an important contributor to hyperbilirubinemia
in the early post-transplant period. The cholestatic effects of 
bacterial infection are mediated directly by endotoxins and 
indirectly by endotoxin-induced cytokines [68]. The clinical 
presentation of cholangitis lenta is usually mild-to-moderate 
elevations of serum bilirubin in a febrile patient. The serum 
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phosphatase level may increase in some cases. The 
histopathological findings of cholangitis lenta are not-specific and
are usually minimal. The diagnosis of cholangitis lenta is based
entirely on clinical criteria. Frequently, the serum bilirubin level falls
with appropriate antibiotic treatment.
Drug-induced cholestasis: Drug-induced cholestasis is a
common entity, seen with several drugs that are used in alloHCT
recipients [3,6]. Different clinical syndromes may be recognized,
with variable degrees of hepatitis in association with cholestasis.
CsA commonly causes a dose-related mild increase in the 
serum bilirubin level due to inhibition of canalicular bile flow and
bile salt secretion [69]. This effect correlates positively with CsA
blood levels. Thus, higher blood CsA levels result in higher total
serum bilirubin values. Tacrolimus also causes cholestasis at
high doses, but not as often as CsA [69]. A high index of 
suspicion is required for the correct diagnosis. The most 
important aspect of treatment of drug-induced cholestasis is
prompt discontinuation of the offending drug. 
TPN has been implicated as being responsible for some of
the mild elevations of serum bilirubin, alkaline phosphatase and
transaminase values seen after alloHCT [2,3,70]. Severe 
hyperbilirubinemia occurs in alloHCT recipients who have sepsis
or hemolysis [70,71]. The histopathological findings of TPN-
related liver toxicity are non-specific. Therefore, the diagnosis is
a clinical one made by exclusion of other causes.
TPN may contribute to the development of biliary sludge,
gallstones and acalculous cholecystitis. Biliary sludge begins to
appear three weeks after the initiation of TPN. Between 4 and 6
weeks of TPN, 50% of alloHCT recipients develop gallbladder
sludge and after six weeks, almost all have ultrasound 
demonstrable biliary sludge. Gallstones are found in 
approximately 20% of alloHCT recipients within four weeks of
transplantation [70,72]. The accumulation of biliary sludge is 
reversible within four weeks of the resumption of oral intake.
Either a reduction or discontinuation of TPN and the initiation
of enteral feeding improve the liver abnormalities occurring as a
result of TPN.
Extrahepatic biliary obstruction: Extrahepatic biliary obs-
truction is rarely seen in individuals with alloHCT. Infiltration of the
common bile duct with the primary hematologic disease process,
CMV-related biliary disease, inspissated biliary sludge or an 
impacted gallstone in the distal common bile duct are the most
common causes of extrahepatic biliary obstruction in alloHCT 
recipients. It is nearly impossible to distinguish between 
extrahepatic and intrahepatic cholestasis in alloHCT recipients 
based upon clinical and laboratory studies. Radiographic 
evaluation is essential.
Cirrhosis
Cirrhosis is an uncommon hepatic complication in alloHCT
recipients. Long-term survivors of HCT may be at increased risk
of developing end-stage liver disease as a result of multiple risk
factors including viral infection, hepatic GVHD and iron overload.
With long-term follow-up, cirrhosis and its various complications
including portal hypertension and hepatocellular carcinoma 
become increasingly important disease confounds. Strasser et
al. [73] reported cirrhosis in 0.8% of alloHCT recipients who had
survived one or more years and in 1.2% of those who survived
five or more years. A rate of 2.2% was reported in those who
had survived 10 or more years and 3.8% in those who survived
20 or more years. HCV infection is the primary risk factor for 
cirrhosis in alloHCT recipients [73]. The rate of progression to
cirrhosis in alloHCT recipients with chronic hepatitis C is more 
rapid than in other patient populations [25,73]. Liver 
transplantation in HCT survivors who develop liver decompensa-
tion is possible. The original alloHCT donor would be an ideal 
potential living donor if no contraindication for live donor 
transplantation is present in either donor or the recipient. 
Liver Biopsy: Abnormalities of liver tests are common after 
alloHCT. Liver biopsy as an important but invasive procedure in
such cases often helps in establishing a specific diagnosis or
another more appropriate prognosis, and can be the ideal 
method for long-term monitoring of the liver disease. Liver 
biopsy is most useful in the evaluation of otherwise unexplained
liver test abnormalities and at excluding other potential 
etiological causes of liver dysfunction. It is also important when
a change in treatment is contemplated. Percutaneous liver 
biopsy in experienced hands is a remarkably safe procedure. In
the early post-transplant period, the presence of severe 
thrombocytopenia, a concomitant hemorrhagic diathesis and
highly elevated aminotransferases levels limit the performance of
a percutaneous liver biopsy, because of the risk of intra-
abdominal hemorrhage and/or liver capsule perforation. A 
transvenous liver biopsy may be a better choice in these cases.
Recent developments in transvenous liver biopsy needles make
this approach more attractive as adequate tissue specimens
and multiple cores can be obtained. Clinically significant bleeding
after a liver biopsy is reported to occur at a rate of 1.3% to
20.2%, with a mortality rate of 0.1% to 0.5% [74,75]. Bleeding
after a liver biopsy is rarely seen if the platelet count is greater
than 50 x 1012/L at the time of the biopsy. A careful assessment
of the potential risk and benefit of a liver biopsy must be made
in each case. 
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